Health & Research Goals
Tesamorelin
Tesamorelina (Egrifta)
Tesamorelin (Egrifta)
Primary Description
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid group conjugated to its N-terminus. This modification stabilizes the peptide against dipeptidyl peptidase IV (DPP-IV) degradation, significantly extending its functional half-life compared to native GHRH. FDA-approved in 2010 under the brand name Egrifta for HIV-associated lipodystrophy (excess visceral adipose tissue accumulation in HIV-infected patients on antiretroviral therapy), tesamorelin has subsequently attracted significant research and clinical interest as a general visceral fat reduction agent and GH secretagogue. It works by stimulating the pituitary gland to release growth hormone in a pulsatile, physiologically regulated manner — preserving hypothalamic-pituitary feedback unlike direct GH administration.
Key Benefits
- Visceral fat reduction
- Improved lipids
- GH optimization
Store lyophilized vials at 2–8°C. After reconstitution with supplied sterile water (Egrifta), use immediately or within 24 hours when refrigerated. Do not freeze reconstituted solution. Protect from light.
Demonstrated Effects
- FDA-approved for HIV-associated lipodystrophy with proven visceral fat reduction
- Significantly reduces visceral adipose tissue (VAT) — the metabolically harmful abdominal fat
- Stimulates natural pulsatile GH release preserving HPG axis feedback
- Improves body composition: reduces trunk fat while preserving lean mass
- Improved lipid profile (reduced triglycerides, LDL cholesterol)
- Potential cognitive benefits — reduces visceral fat-associated neuroinflammation
- Investigated for non-alcoholic fatty liver disease (NAFLD) with promising results
- Better visceral fat targeting than sermorelin — full 44-AA GHRH sequence plus DPP-IV stability
- Improves insulin sensitivity as a secondary effect of visceral fat reduction
- Clinical-grade with established Phase 3 trial safety data
Proposed Mechanisms of Action
1. GHRH Receptor Agonism (Full 44-AA Sequence)
Tesamorelin contains the complete 44-amino acid GHRH sequence plus N-terminal stabilization. It binds GHRH receptors on pituitary somatotrophs with full efficacy, stimulating GH synthesis and pulsatile release — maintaining physiological feedback regulation.
2. DPP-IV Resistance
The trans-3-hexenoic acid N-terminal modification prevents DPP-IV cleavage at the first two amino acids — the primary site of GHRH inactivation. This significantly extends functional half-life compared to native GHRH or sermorelin.
3. GH/IGF-1 Axis Activation for Lipolysis
GH released by tesamorelin stimulation activates lipolysis in visceral adipose tissue specifically — GH receptors are highly expressed in visceral fat. IGF-1 generation contributes to lean mass preservation during this fat mobilization.
4. Hepatic Lipid Metabolism Improvement
GH signaling in the liver promotes fatty acid oxidation and reduces de novo lipogenesis, contributing to both visceral fat reduction and hepatic steatosis improvement.
5. Neuroprotection via IGF-1 and Anti-inflammatory Effects
IGF-1 generated by tesamorelin-stimulated GH has established neuroprotective effects. Additionally, visceral fat reduction decreases systemic and neuroinflammatory burden, contributing to cognitive benefits.
Research Evidence & Clinical Data
Investigated Applications
Visceral Fat Reduction and Body Composition
Anecdotal: HighTesamorelin's most compelling use case is targeted visceral adipose tissue reduction. Clinical trials in HIV lipodystrophy demonstrated 15–20% reduction in visceral fat after 26 weeks. This makes it the most potent available GHRH analogue for visceral fat targeting — more effective than sermorelin for this specific indication.
Preclinical basis: Falutz J et al. (2007, NEJM): Tesamorelin 2 mg daily reduced visceral adipose tissue by 15.2% at 26 weeks versus placebo in HIV lipodystrophy patients.
Cognitive Function and Brain Health
Anecdotal: EmergingThe TESAMORELIN-AD study (Baker et al., 2021) found that tesamorelin improved executive function and memory in older adults with mild cognitive impairment. The mechanism is proposed to involve both GH/IGF-1 effects on neural function and visceral fat-mediated reductions in neuroinflammation.
Preclinical basis: Baker LD et al. (2021): 6 months of tesamorelin improved functional connectivity in the default mode network and executive function scores versus placebo in adults with MCI.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Anecdotal: ModerateTesamorelin has shown significant reductions in liver fat in HIV patients with NAFLD, proposing utility in NAFLD management broadly. The mechanism involves GH-driven lipolysis and improved hepatic lipid metabolism.
Preclinical basis: Stanley TL et al. (2014, Lancet HIV): Tesamorelin significantly reduced liver fat fraction in HIV patients with NAFLD.
Scientific References
- 1.
- 2.
- 3.
- 4.
- 5.
Safety Profile
Common Side Effects
- Injection site reactions (redness, bruising, swelling)
- Peripheral edema (fluid retention, particularly early in treatment)
- Arthralgia (joint pain)
- Carpal tunnel syndrome (from fluid retention)
- Nausea
- Night sweats
- Injection site reactions
- Joint pain
- Edema
Contraindications
- Active malignancy (GH stimulation — theoretical risk)
- Hypothyroidism (untreated — impairs GH response and increases risk of side effects)
- Pregnancy and breastfeeding
- Hypersensitivity to tesamorelin or mannitol
- Prior radiation to the hypothalamus or pituitary (may impair response)
- Active malignancy
- Pregnancy
- Pituitary surgery
Legal & Regulatory Status
FDA-approved as Egrifta (Theratechnologies) for treatment of excess abdominal fat in HIV-infected patients with lipodystrophy (2010). Approved in Canada and other markets. Not approved for general obesity or anti-aging indications. Widely used off-label in anti-aging and metabolic medicine through compounding pharmacies. Not a controlled substance.
Aprobado por la FDA como Egrifta (Theratechnologies) para el tratamiento de exceso de grasa abdominal en pacientes infectados por VIH con lipodistrofia (2010). Aprobado en Canadá y otros mercados. No aprobado para obesidad general o indicaciones anti-envejecimiento. Ampliamente utilizado fuera de etiqueta en medicina anti-envejecimiento y metabólica a través de farmacias de compounding. No es una sustancia controlada.
Research Protocols
Dosing Protocols
Routes of Administration
subcutaneous
Reconstitution Guide
Pharmacokinetics
| Half-Life | Approximately 25–38 minutes. Significantly longer than native GHRH (~7 minutes) due to DPP-IV resistance from N-terminal modification. Once-daily dosing achieves clinically meaningful GH stimulation. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- IGF-1 levels at 1 month, then every 3 months — target upper-normal range for age
- Fasting glucose and HbA1c every 3 months
- Thyroid function every 6 months
- Body composition assessment every 3–6 months
- Lipid panel every 6 months
- Monitor for carpal tunnel or edema symptoms
Critical Warning Signs
- Significant peripheral edema or rapid weight gain from fluid retention
- Carpal tunnel symptoms
- Elevated fasting glucose or new-onset glucose intolerance
- Joint pain worsening
- Visual disturbances (rule out retinopathy)
- Neck mass or swallowing difficulty (thyroid concern)
Featured in Stacking Protocols
Community-researched combinations involving this compound